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We report the largest US case series results using Onyx HD-500 (EV3), a new liquid embolic agent, in the successful treatment
of 21 patients with wide-neck intracranial aneurysms (mean size 4.5mm), which are at increased risk of incomplete occlusion
or recanalization with standard endovascular intervention utilizing detachable platinum coils. All aneurysms were located in
the anterior circulation, and three aneurysms presented as acute subarachnoid hemorrhages. Complete aneurysm occlusion was
present in 19 of 21 patients (90%). On six-month followup, one patient with an initially small residual neck progressed to total
occlusion.Aneurysm recanalizationwasnotdetected inanypatients onmeanfollowup of8.9 monthsin 11patients.Fourpatients
experienced transient neurologic deﬁcits in the immediate postoperative period and one in a delayed fashion. Embolization with
the liquid embolic agent Onyx appears to be a safe and eﬀective endovascular modality of treatment for wide-neck aneurysms or
recurrent aneurysms that had previously failed treatment with detachable coils.
1.Introduction
Treatment modalities achieving endosaccular occlusion of
aneurysms continue to rapidly evolve. As technologies pro-
gress it is imperative to demonstrate improved eﬃciency,
patient care, and clinical outcomes. Liquid embolic agents
designed for aneurysm treatment potentially carry addi-
tional therapeutic beneﬁts over coil embolization including
improved volumetric aneurysm ﬁlling and endothelializa-
tion across the aneurysm neck which can lead to reduced
recanalization rates with fewer procedures and lower ex-
penses. The use of liquid embolic agents stands in contrast
to the recent strategy of ﬂow diversion for the treatment of
intracranial aneurysms.
The Onyx liquid embolic system (EV3, Inc. Irvine, Calif,
USA) is a combination agent of ethylene-vinyl alcohol co-
polymer, dimethylsulfoxide, and tantalum that has been pri-
marily used in the endovascular treatment of arteriovenous
malformations. Since 1999, Onyx has also been used in cere-
bralaneurysmsandhasbeenstudiedinseveralEuropeanand
South American case series [1–3]. Since then, the technique
for its use and types of polymers used have been reﬁned
with a newer high-viscosity agent, Onyx HD 500, designed
speciﬁcally for the endovascular treatment of intracranial
aneurysms. Wereport thelargestpublishedseriesofintracra-
nial aneurysms treated in the United States with Onyx HD
500 for aneurysms with a wide neck (>4mmordome-to-
neck ration <2).
2.Methods
This study was a US single center prospective registry study
that included21 consecutive patients with intracranial aneu-
rysms treated by embolization with Onyx HD 500 between
March 2008 and April 2011 in a single institution. Similar
to patients enrolled in the CAMEO and other Onyx trials,
patients were selected based on aneurysms characteristics
that were diﬃcult to treat by conventional methods of coil
embolization with a neck wider than 4mm or dome-to-neck
ratios less than 2 [3]. Several aneurysms were also selected
thathadrecurredfollowingpriorcoilembolization.Datawas
collectedonpatientspriortotheprocedure,atthetimeofthe
procedure, at discharge, and again at 6–12-month followup.2 International Journal of Vascular Medicine
Clinical data that were evaluated included preoperative co-
morbidities and presenting symptoms, modiﬁed Rankin
scale, cranial nerve deﬁcits, any adverse eﬀects, and changes
in neurologic status as seen in Table 1.
All unruptured aneurysms were pretreated with clopi-
dogrel 75mg per day and aspirin 81mg for at least 10 days
before the procedure. Patients with subarachnoid hemor-
rhage (SAH) were loaded with 600mg of clopidogrel dur-
ing the procedure through the nasogastric tube. In only
one patient was Enterprise stent (Codman Neurovascular,
Raynham, MA, USA) assistance utilized at the time of onyx
embolization; however, ﬁve patients were coiled previously,
andoneofthemhadastent-assistedcoilingthatpresentedon
follow upwith a recurrence. In no patientwas adjunctivecoil
embolization employed. The procedure time from micro-
catheter insertion to removal ranged from 25 to 120 minutes
with a mean of 56 minutes. The average time under ﬂuoros-
copy was 75 minutes. The total volume of onyx used ranged
from 0.2mL to 8.4mL with a mean of 1.2mL.
All patients were treated under general anesthesia and
full systemic anticoagulation with heparin. Sincewe perform
all of our endovascular aneurysm treatments under general
anesthesia, neurophysiological monitoring was used as a
substitutefortheneurologicalexamduringtheseprocedures.
Electrophysiologic monitoring was performed for continu-
ous BAERs, SSEPs, and EEG. Activated clotting times were
maintained greater than 250 seconds throughout the entire
case. Our technique used for Onyx injection is similar to
those previously described as seen in Figures 1 and 2 [2–8].
After the Onyx embolic agent is dry heated and shaken, a 6F
guide catheter is placed in the internal carotid artery and a
DMSO-compatible Hyperglide balloon (EV3, Irvine, Calif,
USA) positioned and inﬂated to allow its middle portion
to cover the neck of the aneurysm. The microcatheters
utilizedinthis studytoaccesstheaneurysm weretheDMSO-
compatible Rebar 14 (EV3) or Echelon 10, which are placed
within the mid-portion of the aneurysm. Next, with the
balloon inﬂated, contrast agent is slowly injected to ensure
an eﬀective seal test, demonstrating stasis of the contrast
in the aneurysm and allowing estimation of the amount of
balloon inﬂation needed for complete aneurysm occlusion
while avoiding leakage of the embolic agent. The balloon is
deﬂated at this point.
Next,saline is ﬂushed throughthemicrocatheter, and the
dead space is ﬁlled with DMSO. Onyx is then carefully in-
jected until the material approaches the end of the micro-
catheter at the recommended rate of 0.2mL/2min. With the
DMSO then displaced, the balloon is inﬂated after 0.15mL
of onyx is injected to ﬁll part of the microcatheter dead
space. At this point, Onyx is injected to ﬁll the aneurysm
sac with the balloon inﬂated. In our institution, with the use
of intraoperative neurophysiologic monitoring, the balloon
is continuously inﬂated as long as the monitoring is stable.
We do not interrupt our injection to deﬂate the balloon.
Onyx is allowed to laminate around the balloon, creating an
alpha sign, in the parent artery to cover the aneurysm neck,
ensuring a complete and durable occlusion and reducing the
risk of aneurysm recurrence. With conﬁrmation of adequate
aneurysm obliteration, there is a 10-minute hold period to
allow complete solidiﬁcation of the cast with the balloon de-
ﬂated. The balloon is then inﬂated for counter resistance and
the microcatheter removed by gentle but brisk traction.
3.Results
Patient’s ages ranged from 35–85 years with a mean age of 57
asseeninTable1.ThreepatientspresentedasacuteHuntand
Hess Grade IV Subarachnoid Hemorrhage, 4 had a previous
history of SAH, and the remaining 11 aneurysms were un-
ruptured. Five patients presented with cranial nerve deﬁcits.
Of these 3 had cranial nerve III palsies from cavernous ca-
rotid aneurysms, and two had visual ﬁeld deﬁcits from oph-
thalmic artery aneurysms. Eleven patients presented with
headaches, while 3patients’aneurysms were completelyinci-
dental ﬁndings on MRI/A. Five patients had been previously
treated with coil embolization but had recanalized, and 1
patient was previously coiled with stent assistance incom-
pletely. All patients underwent cerebral digital subtraction
angiography prior to treatment.
All of the aneurysms were located in the anterior circula-
tion arising on a segment of the internal carotid artery. One
aneurysm was located in the clinoid segment, 4 superior hy-
pophyseal, 4 cavernous carotid, 5 posterior communicating,
6 ophthalmic, and 1 in the anterior choroidal segment. Ten
aneurysms were located oﬀ the left ICA, while 9 were right
sided. Fourteen aneurysms were small (<8mm), six were
large (8–24), and one was giant (≥24mm). Eleven aneu-
rysms had necks greater than 4mm with a mean neck length
of 4.5mm. The average parent artery diameter was 4.3mm.
All 21 patients were successfully treated with Onyx HD
500, and 19 of 21 had complete occlusion as the immediate
angiographic result with two patients displaying a small re-
sidual neck as seen in Table 2. One Grade IV Subarachnoid
hemorrhage patient required decompressive hemicraniec-
tomy postoperatively due to increased intracranial pressures,
and another patient with a grade V SAH ultimately pro-
gressed to brain death. Three patients had minor unin-
tentional embolic migration into the parent artery without
ﬂow limitation. On followup parent artery stenosis was not
observed. Initially, 5 of the 21 patients experienced transient
neurologicadverse eventsasdescribedin Table 3.Allpatients
undergoing their six-month followup had improved to their
baseline neurologic condition. Ten of 21 patients (47%) had
followup angiography within one year (one patient with
follow-upMagneticResonanceAngiography)andallofthese
patients achieved complete occlusion.
4.Discussion
Since the publication of the results of ISAT and ISUIA, the
development of endovascular techniques utilizing platinum
coils has been a dominant tool in the armamentarium of
neurovascular interventionalists to achieve complete occlu-
sion and prevent aneurysm rupture [9, 10]. However, aneu-
rysms with wide necks (>4mm), dome-to-neck ratios less
than 1.5, or very large in dome height that have been treated
with coils are associated with high rates of recanalization.International Journal of Vascular Medicine 3
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LICA
(a)
LICA
(b) (c)
(d)
LICA
(e)
LICA
(f)
LICA
(g)
Figure 1: Angiograms showing the stages in the Onyx embolization of a 6.5mm left ophthalmic artery aneurysm that was previously
untreated. (a)Digitalsubtractionangiography(DSA)showinga6.5mmleftophthalmicarteryaneurysminthefrontalandmagniﬁedfrontal
view (b). (c) Frontal projection of DSA showing “seal test” with Rebar 14 microcatheter in midportion of aneurysm with 4 ×30 Hyperglide
balloon inﬂated. (d) Initial injection of Onyx HD 500. (e) Frontal and lateral. (f) DSA projection displaying immediate 95% occlusion with
neck remnant. (g) Nine-month followup showingprogression to complete occlusion in the frontal and lateral projections (h).
This deﬁciency in the endovascular treatment of aneurysms
hasledtothedevelopmentofnewertechniquesandmaterials
to completely occlude these diﬃcult-to-treat cerebral aneu-
rysms.
Onyxliquidembolicisabiocompatiblenonadhesiveagent
composed of ethylene-vinyl alcohol copolymer and dim-
ethyl sulfoxide (DMSO) solvent added to tantalum powder
to make the solution radioopaque. Being a liquid embolic
agent allows Onyx to ﬁll 100% of the aneurysm sac volume.
Originally, diﬀerent polymer concentrations Onyx 18 and 34
(6% and 8%) were used in AVM embolization. An Onyx
12% polymer concentration was then initially used for an-
eurysm embolization until Onyx HD (high density; 500cP)
was developed with a 20% copolymer concentration withInternational Journal of Vascular Medicine 5
LICA
(a)
LICA
(b) (c)
(d)
LICA post 2.4CC Onyx HD 500
(e)
LICA post 2.4CC Onyx HD 500
(f)
Figure 2: Angiograms displaying stages of Onyx embolization of an 85-year-old woman who presented with progressive vision loss and
found to have 14mm left ophthalmic artery aneurysm. (a) DSA showing a 14mm L ophthalmic aneurysm in the Townes and Lateral (b)
projections. (c) Magniﬁed Townes projection showing 4 × 30 Hyperglide balloon inﬂated with contrast ﬁlling aneurysm. (d) Magniﬁed
frontal DSA projection showing Onyx ﬁlled aneurysm sac with complete ﬁlling. (e) DSA ﬁnal runs showing completely occluded aneurysm
in the frontal and lateral (f) projections.
an increased viscosity to lessen the likelihood of reﬂux into
the parent artery. Onyx utilizes a balloon remodeling tech-
nique that may enable better control of the neck and parent
v e s s e lc o m p a r e dt ot r a d i t i o n a lc o i l i n g[ 7]. There are also re-
ports of Onyx inducing more neoendothelialization over the
neck of the aneurysm relative to coils [6, 11].
There havebeenpreviousreportsofthe endovascularuse
of Onyx in intracranial aneurysms beginning with Mawad
et al. describing embolization of 11 large and giant intracav-
ernous aneurysms with an initial 82% complete occlusion
and 91% at followup in 6 or 12 months [5]. They did not
report any recanalization. The European CAMEO trial was
the ﬁrst multicenter trial with Onyx embolization that de-
scribed 100 treated aneurysms with an occlusion rate at 1-
year followup ranging from 93% in small aneurysms to 57%
in giant aneurysms with an overall occlusionrate of79% [3].
They retreated 10% of patients and reported an 8% perma-
nent morbidity and 2% mortality rate. Following these trials
with promising initial results, Onyx HD 500 was developed
with a greater viscosity to reduce the risk of parent vessel
occlusion and distal migration that were seen in these prior
trials. Weber et al. was the ﬁrst European trial to report their
initial use Onyx HD 500 in 22 aneurysms with an immediate
occlusion rate of 82% and 91% at approximately one year
[8]. Temporary or minor complications were reported in
14% of patients, more permanently in 4.5% and 11% of
aneurysms recanalized. They di dn o tr e p o r ta n yd e a t h s .T h e
largest South American Onyx HD 500 trial to date was
published by Piske et al. which reported on 84 wide-neck
aneurysms with a 66% total occlusion on short-term follow
up, 85% at 6 months, and 90% at 18 months [6]. They
reported progression from incomplete to completeocclusion
in 68%, with recanalization in 5% in which 2 patients (3%)
required retreatment. Their reported mortality was 2.9%
with a permanent morbidity of 7%. Simon et al. was the ﬁrst
US group to discuss their preliminary experience with Onyx
HD 500 in 12 intracranial aneurysms [7]. They described
initial angiographic results in which all aneurysms were 90%
or more occluded. All patients with followup six-month
DSA displayed durable occlusion. They experienced one
complication with ophthalmic occlusion and no mortalities.
Our results in 21 patients with wide-neck aneurysms
treated with Onyx HD 500 are compared favorably with
those of the CAMEO trial and other series and better than
those reported for coil embolization as seen in Table 4.1 9
patients achieved immediate complete occlusions, and one6 International Journal of Vascular Medicine
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Table 3
Case no. Timing of followup Degree of change of
followup angiogram Followup raymond scale Followup angio %
occlusion Followup mRS
1 9 months No change Complete occlusion 100% 0
2 7 months No change Complete occlusion 100% 0
6 12 months No change Complete occlusion 100% 0
7 9 months No change Complete occlusion 100% 0
8 11 months No change Complete occlusion 100% 0
9 6 months No change Complete occlusion 100% 1
10 8 months No change Complete occlusion 100% 0
11 9 months Increased occlusion Complete occlusion 100% 0
12 12 months No change Complete occlusion 100% 0
14 6 months (MRA) No change Complete occlusion 100% 0
Table 4
Authors Date published Journal #A n e u r y s m s
treated Primary outcome % Mortality % Permanent disability
attributed to procedure
Mawad et al. [5] Mar, 2002 J Neurosurg 11 GOS 9% 9%
Molyneux et al. [3] Jan,2004 AJNR 97 Percent occlusion 2% 8%
Lubicz et al. [2] Apr, 2005 AJNR 41 mGOS 3% 7%
Weber et al. [8] Sept, 2005 AJNR 22 Percent occlusion 0% 0%
Cekirge et al. [1] Jan,2006 Neuroradiology 100 mRS 3% 8%
Piske et al. [6] May, 2009 Neurosurgery 84 Percent occlusion 3% 7%
Simonet al. [7] Sept, 2010 Neurosurgery 12 Durable occlusion 0% 8%
initially near-complete occlusion progressed to complete oc-
clusion.Eight patients (38%) experienced adverse events fol-
lowingtheprocedureincludingworsening ofpreexisting cra-
nial neuropathies in 2 patients, transient visual disturbance
in 1 patient, TIAs in 1 patient, and femoral access complica-
tionsin1patient;2patientswithSAHhadcomplicationsfol-
lowing the procedure that were due to their primary disease
(1 grade IV patient required hemicraniectomy and 1 grade
V patient died). Of the initial adverse events in unruptured
aneurysms, none produced permanent morbidity with all
neurologicalsequelaeresolving completelyatdischarge oron
followup.
These results are encouraging and must be weighed
against recent aneurysm treatment strategies utilizing endo-
luminaltreatments and ﬂow diversion.These techniques aim
to induce aneurysmal thrombosis by diverting the ﬂow away
from the aneurysm; however, this obliteration eﬀect takes
place in a delayed fashion and requires weeks to months
for full eﬀect. In the setting of acute SAH, ﬂow diversion
is relatively contraindicated when considering that the risk
of rerupture is close to 20% in 2 weeks and 50% by 6
months. Also,ﬂow diversionstentscannotbeusedatarterial
bifurcations. Further, with early reports on the Pipeline stent
describing some delayed aneurysm ruptures and intra pa-
renchymal hemorrhages ﬂow diversion stent’s eﬃcacy and
adverse eﬀect proﬁle cannot be assumed until larger series
are reported [12].
Atthispoint in time, Onyx HD500has still some speciﬁc
indications, such as multilobulated aneurysms close to a
bifurcation (like our case in Figure 3), wide-neck aneurysms
below 10mm (considering the FDA has only approved the
pipeline embolization device for aneurysms >10mm), the
setting of subarachnoid hemorrhage, in previously stented
aneurysms where pipeline cannot provide the diversion de-
sired, and in small recurrences after coil embolization where
Onyx HD 500 can eﬀectively seal the neck of the aneu-
rysm.
In our series, we treated three SAH patients (2 grade IV
and one grade V) and immediately achieved complete aneu-
rysm occlusion in all patients. Two patients were eventually
discharged to inpatient rehabilitation facilities with perma-
nent disabilities, and the other ultimately proceeded to brain
death. Similar to ﬂow diversion techniques however, Onyx
embolization requires antiplatelet agents preoperatively and
postoperatively, making its use in patients with an acute
aneurysm rupture less than ideal. However, the morbidity
and mortality of an otherwise unprotected and recently
ruptured aneurysm and the lack of other options at the time
(based uponaneurysmcharacteristics) madethe useofOnyx
HD 500 a necessity.
Taken together, our overall results using Onyx HD 500
were encouraging, but will necessarily need to be conﬁrmed
with largerseries and incomparison tonewer self-expanding
stent-assisted coiling and ﬂow diversion techniques.8 International Journal of Vascular Medicine
(a)
LAO/RAO −141
CRAN/CAUD −25
F
L
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R
(b)
LICA PE
Onyx 500 4CC
Enterprise stent 4.5 ×28
(c)
LICA PE
Onyx 500 4CC
Enterprise stent 4.5 ×28
(d)
Figure 3:AngiogramsdemonstratingstagesofOnyxembolizationofa53-year-old manpresenting with severeheadaches andfoundto have
19×13mm left anterior choroidal aneurysm with 5mm neck as seen in the A/P (a) and 3D reconstruction (b). (c) DSA showingmagniﬁed
frontal and lateral. (d) Projection after Onyx embolization and placement of Enterprise stent.
5.Conclusion
Onyx HD 500 appears to be a safe and eﬀective endovascular
modality of treatment for wide-neck aneurysms that are
not amenable for, or had previously failed treatment with
detachable coils. With an adequate patient selection, this
method may be a better alternative than coiling in regards to
packing density, intraoperative rupture, and recurrence rate.
In the ﬂow diversion era, Onyx HD 500’s use needs to be
redeﬁned; however it remains a valuable tool in the endovas-
cular armamentarium.
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